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Abstract
Several studies of tumors have revealed substantial numbers of clonally expanded somatic
mutations in mitochondrial DNA (mtDNA), not observed in adjacent intact tissues. These findings
were interpreted as indicating the involvement of mtDNA mutations in tumorigenesis. Such
comparisons, however, ignore an important confounding factor: the monoclonal origin of tumors
as opposed to the highly polyclonal nature of normal tissues. Analysis of recently published data on
the incidence of somatic mutations in nontumor monoclonal cells suggests that, contrary to the
prevailing view, the process of tumorigenesis may be accompanied by active selection against
detrimental mtDNA mutations.
Accumulation in mutations in mtDNA, leading to an
impairment of mitochondrial function, has been impli-
cated in the etiology of aging [1,2] and of several degener-
ative pathologies including Parkinson's [3], Alzheimer's
diseases [4], and diabetes [5]. Similarly, mtDNA mutation
is thought to be involved in tumorigenesis based on the
presence of novel hetero- and homoplasmies in a number
of neoplasms [6]. In the case of degenerative diseases,
intracellular clonal expansion of detrimental mtDNA
mutations could play a causative role, resulting in cell loss
and/or significant functional impairment of affected cells.
This logic is not likely to apply to tumorigenesis, and it is
not entirely clear at what stage of tumorigenesis a defi-
ciency in aerobic metabolism would confer a selective
advantage.
Several different scenarios, linking mtDNA mutations to
tumorigenesis, can be envisioned. Cells with an elevated
mtDNA mutational load may be more susceptible to car-
cinogenesis due to increased production of ROS by a dys-
functional electron transport chain, which may in turn
promote mutagenesis of nuclear genes. On the other
hand, cells with relatively intact oxidative phosphoryla-
tion would have enhanced prospects for survival. It is also
possible that carcinogenesis is influenced to a larger extent
by accumulation of mtDNA mutations in organs distal to
the tissue of origin, by creating a systemically permissive
environment for development of tumors.
In a number of studies on mtDNA mutations derived
from diverse tumors [7-20], the percentage of samples
with clonally expanded mtDNA mutations ranged from
27% to almost 80%, averaging 54 ± 5% (mean ± SE; see
Suppl. Table 1). These findings led investigators to the
conclusion that mtDNA mutations are either more com-
mon in carcinogenesis, or in some way predispose to it
[8,21]. It is not possible, however, to infer the functional
importance of mitochondrial DNA mutations to
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tumorigenesis from these comparisons of tumors to adja-
cent normal tissue. Such studies are confounded by the
well-established monoclonal origin of tumors in contrast
to the highly polyclonal derivation of normal tissues.
Therefore, while the occurrence of hetero- or homoplas-
mic mutations to mitochondrial DNA is easily detectable
in tumor cells, low-level heteroplasmy remains undetec-
ted by prevailing methods in essentially all normal tis-
sues. In addition, tumor cells are generally more
mitotically active than normal diploid cells [22] and, as
clonal expansion of mutations is thought to result from
the random distribution of mutations over multiple repli-
cative cycles [23], tumors could display higher rates of
subclonal development and detection of new heteroplas-
mies, for this reason alone. Consequently, the validity of
direct comparisons between tumor and adjacent normal
tissues is questionable, when such studies fail to address
the frequency of mitochondrial DNA mutations in indi-
vidual normal cells or clones of normal cells that have
undergone a comparable expansion.
This type of analysis has been recently performed in both
dividing and non-dividing normal cells [24-27]. In a
study on individual buccal cells and myocytes, direct
sequencing of the control region (a non-coding 1121 bp
fragment of mtDNA containing several replicational and
transcriptional control elements) revealed clonally
expanded mutations in 36% of both cell types from older
individuals, whereas cells from younger subjects were free
from homoplasmies [24]. In another study from the same
group, homoplasmy in the D-loop was detected in 20%
(5/24) of buccal cells [25], thus demonstrating that clonal
expansion is not a tumor-specific phenomenon. Using
available data on tumor dynamics the authors estimated
the occurrence of clonal expansions in the entire mtDNA
of tumors at 58%, and noted the similarity of this fre-
quency to reported empirical values [8,21].
Our analysis of data from available literature (Fig. 1, Addi-
tional file 1, Table 1) supports the above argument [23],
that normal cells and tumors have very similar frequen-
cies of clonally expanded mutations in the D-loop (24 ± 5
vs. 30 ± 5%) and in the entire mitochondrial genome (48
± 12% vs. 54 ± 5%). However, analysis of the mutation
distribution within mtDNA in tumors and normal cells
reveals a more complex pattern, in which the similar totals
hide very disparate components. Nearly half of the muta-
tions found in tumors (47 ± 7%) are located in the control
region (Fig. 2, Additional file 1, Table 2). The remaining
mutations comprise 13% silent substitutions in protein-
coding sequence, 21% missense/nonsense changes in the
same regions, and 19% changes in sequences templating
mitochondrial RNAs. The only fully comparable normal-
tissue dataset available is derived from the analysis of
complete mtDNA sequences in 60 colonic crypts from five
healthy individuals [26]. Colonic crypts are thought to be
of essentially clonal derivation [28], and thus provide an
Incidence of somatic mutations in tumors and normal cells  (The datasets from colonic crypts [26] have been modified in  order to eliminate bias introduced by preferential analysis of  COX negative crypts; for this purpose, all functionally detri- mental mutations involving COX subunits in COX-negative  crypts were removed from consideration) Figure 1
Incidence of somatic mutations in tumors and normal cells 
(The datasets from colonic crypts [26] have been modified in 
order to eliminate bias introduced by preferential analysis of 
COX negative crypts; for this purpose, all functionally detri-
mental mutations involving COX subunits in COX-negative 
crypts were removed from consideration).
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Distribution of mtDNA mutations in tumors and normal cells Figure 2
Distribution of mtDNA mutations in tumors and normal 
cells. (P values refer to t-test comparisons between tumor 
and nontumor cells; detailed information is provided in Addi-
tional file 1, Table 2).
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appropriate control for cancer cells. Compared to cancer
cells, the incidence of D-loop mutations in mtDNA of
colonic crypts was more than 3-fold lower (P < 0.0002),
whereas the percentage of both mutations in RNA
sequences and missense/nonsense mutations in protein
coding sequences was about 75% higher.
The incidence of somatic mutations in the control region
of mtDNA is similar for tumors and crypt cells, consistent
with these cells having comparable mitotic activity. On
the other hand, the ratio of mutation frequencies (per 1
kb) in the D-loop, versus the rest of mtDNA, is much
higher in tumors (13.5) than in normal epithelial cells
(2.4), suggesting a rather different distribution of muta-
tions or (more likely) very different selective pressures act-
ing on these cell types with respect to mitochondrially
encoded subunits. These data support strong selection
against detrimental mtDNA mutations in tumor cells,
implying that successful tumorigenesis requires intact
mitochondria.
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Numerical data on incidence and distribution of mtDNA mutations in 
tumors and normal cells.
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